Exscientia (NASDAQ:EXAI) Sees Large Volume Increase - Here's Why

Exscientia plc (NASDAQ:EXAI - Get Free Report) shares saw unusually-strong trading volume on Monday . Approximately 1,195,302 shares traded hands during mid-day trading, an increase of 90% from the previous session's volume of 630,734 shares.The stock last traded at $6.13 and had previously closed at $5.44.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Barclays reiterated an "equal weight" rating and set a $5.00 price target on shares of Exscientia in a research report on Tuesday, August 13th. TD Cowen reaffirmed a "hold" rating on shares of Exscientia in a research report on Friday, August 9th.

Exscientia Stock Performance

The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $702.37 million, a price-to-earnings ratio of -4.72 and a beta of 0.83. The company has a 50-day moving average price of $5.00 and a 200-day moving average price of $5.12.

Exscientia (NASDAQ:EXAI - Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.05). The business had revenue of $5.60 million during the quarter. Exscientia had a negative return on equity of 37.56% and a negative net margin of 620.99%. As a group, equities research analysts forecast that Exscientia plc will post -1.25 earnings per share for the current year.

Institutional Trading of Exscientia

A number of hedge funds and other institutional investors have recently modified their holdings of EXAI. China Universal Asset Management Co. Ltd. grew its position in Exscientia by 66.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,576 shares of the company's stock worth $47,000 after buying an additional 3,821 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Exscientia in the 2nd quarter worth $54,000. International Assets Investment Management LLC acquired a new stake in shares of Exscientia during the third quarter worth $77,000. Federated Hermes Inc. purchased a new stake in shares of Exscientia during the second quarter valued at $115,000. Finally, EntryPoint Capital LLC boosted its position in shares of Exscientia by 22.8% in the 1st quarter. EntryPoint Capital LLC now owns 31,171 shares of the company's stock valued at $178,000 after purchasing an additional 5,784 shares during the period. Institutional investors own 41.58% of the company's stock.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.